The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
HDACi – Targets beyond chromatin
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Lysine Acetylation: Codified Crosstalk with Other Posttranslational Modifications
Yang, X.-J., & Seto, E. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.07.002 · Cited by 1,006
Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation
Jeong, J.-W., Bae, M.-K., Ahn, M.-Y., Kim, S.-H., Sohn, T.-K., Bae, M.-H., Yoo, M.-A., Song, E. J., Lee, K.-J., & Kim, K.-W. (2002) · Cell · doi:10.1016/s0092-8674(02)01085-1 · Cited by 716
Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523 · cited 4×
“role of RLIM in HDAC2 turnover [70], degradation of AML1-ETO and PML–RARa does not require RLIM.”
BackgroundInfluentialModulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228
Yu, X. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.7.504 · Cited by 360
Wang, R., Cherukuri, P., & Luo, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413930200 · Cited by 275
Cited by
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Nonhistone protein acetylation as cancer therapy targets
Singh, B. N., Zhang, G., Hwa, Y. L., Li, J., Dowdy, S. C., & Jiang, S.-W. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.62 · Cited by 300
Pazolli, E., Alspach, E., Milczarek, A., Prior, J., Piwnica-Worms, D., & Stewart, S. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3386 · Cited by 192
Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders
Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061333 · Cited by 171
HDAC2: a critical factor in health and disease
Krämer, O. H. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.007 · Cited by 157
Self-citation
Metadata
- Authors
- Buchwald, M., Krämer, O. H., & Heinzel, T.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 280
- Issue
- 2
- Pages
- 160-167
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2068337524
- Cited by
- 159
- References
- 10
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HDACi – Targets beyond chromatin. https://app.cochat.ai/papers/10.1016/j.canlet.2009.02.028
- The paper
- Buchwald, M., Krämer, O. H., & Heinzel, T. (2009). HDACi – Targets beyond chromatin. Cancer Letters. https://doi.org/10.1016/j.canlet.2009.02.028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.